Intensity Therapeutics to present two posters ay SABCS

Intensity Therapeutics (INTS) announces it will present two posters at the San Antonio Breast Cancer Symposium, SABCS, in San Antonio, TX being held at the Henry B. Gonzalez Convention Center. Poster PS5-08-16 Reports Early Observations from the INVINCIBLE-4 Study, an Ongoing Randomized, Presurgical Phase 2 Clinical Trial for Triple Negative Breast Cancer continue to show favorable safety: 50% fewer grade 3 or higher Adverse Events were observed in the INT230-6 cohort compared to the Standard of Care neoadjuvant chemotherapy alone cohort. Poster PS4-10-15 Describes An Overview of a Potential Phase 3 Clinical Study Design with INT230-6 plus standard of care with and without the toxic anthracycline, doxorubicin